MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO Complete if Known 10/784,917 INFORMATION DISCLOSURE **Prior Application Number** STATEMENT BY APPLICANT Prior Appl. Filing Date 02/24/2004 JAN 1 2 7006 Peng Cho TANG First Named Inventor Date Submitted: January 12, 2006 **Group Art Unit** 1626 (use as many sheets as necessary) **Examiner Name** Stockton, Laura **Attorney Docket Number** 034536-1150 Sheet of 3 1

					F	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Office	oreign Patent D Number ⁴	Kind Co	ode ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
Æ	C1	AU	286870			IMPERIAL CHEMICAL INDUSTRIES OF AUSTRALIA AND NEW ZEALAND LIMITED	05-11-1967		
E S	C2	CA	2,012,634		A1	UNIVERSITY OF BRITISH COLUMBIA	09-20-1991		
H	СЗ	нυ	65452			RICHTER GEDEON BEGYESZETI GYAR RT	06-28-1994		
-88	C4	wo	92/03736		A1	SEIKAGAKU KOGYO KABUSHIKI KAISHA	03-05-1992		
:sel	C5	wo	94/10202		A1	GENENTECH, INC.	05-11-1994		
AR .	C6	wo	96/32380		A1	PHARMACIA S.P.A.	10-17-1996		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰
B	C7	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990) (Abstract considered by examiner, best available full reference attached)	
B	C8	Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo [2, 1-b]thiazolymethylene)-2-indolinones," <u>Eur. J. Med. Chem</u> . 32:919-924 (1997)	
B	C9	Baserga, "Oncogenes and the strategy of growth factors," <u>Cell</u> 79:927-930 (1994)	
70 20 20 20 20 20 20 20 20 20 20 20 20 20	-C19/	Beilstein Reg. No. 233511 (1997)	- 1

-		and the state of t	market an electrical and the end	THE RESERVE OF THE PARTY OF THE
Examiner Signature	Ham S.	Stoll	Date Considered	3/27/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁹Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

WASH_1526797.1

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO				Complete if Known			
	INFORMATION	DISCLO	SURE	Prior Application Number	10/784,917		
	STATEMENT B	3Y APPLI	CANT	Prior Appl. Filing Date	02/24/2004		
Date Submitted: January 12, 2006				First Named Inventor	Peng Cho TANG		
	Date Submitted.	January	2, 2006	Group Art Unit	1626		
	(use as many she	ets as ne	cessary)	Examiner Name	Stockton, Laura		
Sheet	2	of	3	Attorney Docket Number	034536-1150		

160		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [®]
AC	C11	Borsche et al., "Über nielkernige kondersierte systeme mit heterocyclischen ringen," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)	
A	C12	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>Chemical Abstracts</u> , Vol. 101, abstract no. 37875 (1984)	
M	C13	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidine-indol-2(3H)-ones," <u>Chemical Abstracts</u> Vol. 82, abstract no. 72891 (1975)	
S	C14	Houben-Weyl., "Substance Index," Cyclic Compounds V Bicyclic Compounds 1 E23X:834-1018 (1999)	
f&	C15	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1 <i>H</i>)-benzimidazolone-and oxindole-1 acetic acids" Chemical Abstracts, Vol. 118, abstract no. 254813 (1993)	er date er date
A	C16	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," Chemical Abstracts, Vol. 76, abstract no. 21121 (1972)	
AR .	C17	Schindler et al., "Dibenz[<i>b,f</i>]-azocin-Derivate," <u>Helvetica Chimica Acta</u> 49:985-989 (1966)	
R	C18	Stetinova et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," Collection Czecholslov. Chem. Commun. 42:2201-2206 (1976)	

Examiner Signature Considered 3 27/06	Contract of the Contract of th		AND THE REPORT OF THE PROPERTY OF THE PARTY	and there were about the distriction of the St. w. at The St. dece.	 			_
		X	In P. Sto		 3	27/	202	5. 10

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

WASH_1526797.1

.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in donformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO Complete if Known 10/784,917 INFORMATION DISCLOSURE **Prior Application Number** STATEMENT BY APPLICANT Prior Appl. Filing Date 02/24/2004 Peng Cho TANG First Named Inventor Date Submitted: January 12, 2006 1626 **Group Art Unit** (use as many sheets as necessary) **Examiner Name** Stockton, Laura **Attorney Docket Number** 034536-1150 Sheet 3 of 3

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁰ ·
NOT	C19_	Sumpter and Miller, "Chapter IV – Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole</u> Systems, Interscience Publishers, Inc., New York, pp. 134-153 (1954)	
n/a	- 620 -	von Dobeneck et al., "α.β'-Diindolyknethane und-methene. Der Urorosein-Chromophor," <u>Zur Chemie des Indols</u> VI:1347-1357 (1969)	
8 8	C21	Wahl, Beilstein Reg. No. 191439, <u>Bull. Soc. Chim. Fr.</u> , page 1038 (1909)	
**	C22	Wahl, Bull. Soc. Chim. Fr., pages 1035-1038 (1909) (see C21, partial duplicate)	
B	C23	Winkelmann et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part I)," <u>ArzneimForsch./Drug Res.</u> 27(II):2251-2263 (1977)	
æ	C24	Wright, Beilstein Reg. No. 235900, <u>J. Amer. Chem. Soc.</u> 78:221-224 (1956)	
88	C25	Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Institute of Chemistry</u> . <u>Academy of Science of the Moldavian SSR</u> , Kishinev pp. 34-37 translated from <u>Khimiya</u> <u>Geterotsiklicheskikh Soedinenii</u> 1:40-44 (1973) (Abstract considered by examiner, full document enclosed, not In English)	

Control of the contro		The state of the s
Examiner Signature	Date Considered	327/06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

WASH_1526797.1

N

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in donformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). °For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁰Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. ⁰Applicant is to place a check mark here if English language Translation is attached.